Aimovig market seen growing on migraine prevention demand

The Business Research Company says Aimovig’s global market is set to expand through 2035, driven by rising migraine diagnoses, broader insurance coverage, and growing use of preventive biologics. North America held the largest regional share in 2025, while the report points to personalized medicine and higher healthcare spending as key tailwinds.

Why it matters: - Aimovig sits in a fast-growing migraine treatment category where prevention is becoming a bigger priority than short-term symptom relief. - The market outlook matters for drugmakers, neurologists, payers, and specialty pharmacies as preventive care gains ground. - The report frames Aimovig as part of a broader shift toward CGRP-targeted therapies and biologic treatments for migraine prevention.

What happened: - The Business Research Company published its Aimovig Global Market Report 2026, covering market size, trends, and forecast data for 2026-2035. - The report says the Aimovig market expanded on the back of high migraine prevalence, limited effectiveness of traditional treatments, approval of CGRP inhibitors, neurologist acceptance, and demand for preventive therapies. - The report said North America held the largest share of the Aimovig market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

The details: - Aimovig is a preventive migraine treatment that targets the calcitonin gene-related peptide receptor. - Blocking CGRP reduces the frequency and severity of migraine attacks. - The report expects further growth from more chronic migraine diagnoses, broader insurance coverage, wider acceptance of biologic drugs, better patient outcome data, and more specialist neurology visits. - Key trends listed in the report include more CGRP-targeted therapies, stronger emphasis on prevention, a shift from acute to long-term management, broader biologic use, and growth in specialty pharmacy distribution. - The report says migraine prevalence is being driven by changing lifestyles, higher stress, genetic factors, hormonal changes, and better diagnostic awareness. - Aimovig is the first FDA-approved CGRP receptor blocker. - The report says Aimovig also aligns with AI-powered migraine management platforms that analyze and predict individual migraine triggers. - In March 2024, the House of Commons Library reported that around 10 million people in the UK suffer from migraines. - The UK’s Office for National Statistics said healthcare spending rose 5.6% from 2022 to 2023, reaching about $317.63 billion (£292 billion) in 2023. - The Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - The report is signaling that migraine care is moving toward longer-term disease management, not just treatment after symptoms start. - Higher healthcare spending and broader insurance coverage could make preventive biologics easier to access. - Personalized medicine is becoming a stronger commercial theme for therapies like Aimovig because providers are looking for more targeted treatment choices. - North America’s lead likely reflects stronger healthcare infrastructure, higher patient awareness, and wider insurance coverage.

What's next: - The report expects CGRP-based and biologic migraine treatments to keep expanding through 2035. - Specialty pharmacy channels may gain more importance as preventive migraine treatment becomes more common. - More information is available through the company’s free sample request page.

The bottom line: - Aimovig’s market story is less about a single drug and more about a larger shift toward preventive, personalized migraine care.